Stetefeld Henning R, Lehmann Helmar C, Fink Gereon R, Burghaus Lothar
Department of Neurology, University Hospital Cologne, Cologne, Germany.
Department of Neurology, University Hospital Cologne, Cologne, Germany.
J Stroke Cerebrovasc Dis. 2014 Oct;23(9):e423-5. doi: 10.1016/j.jstrokecerebrovasdis.2014.05.034. Epub 2014 Aug 20.
The association of a posterior reversible encephalopathy syndrome (PRES) without arterial hypertension with autoimmune-mediated inflammatory neuropathies such as Guillain-Barré syndrome (GBS) is a rare and poorly understood phenomenon. To date, PRES has been described as initial manifestation, coincidental finding, or adverse event subsequent to immunomodulatory treatment with intravenous immunoglobulin (IVIG) in cases of axonal and demyelinating GBS as well as in Miller-Fisher syndrome (MFS). We here report a case of MFS/Bickerstaff brain stem encephalitis (BBE)-overlap syndrome and nonhypertensive PRES that occurred in close temporal association with IVIG treatment and caused stroke. Immunoadsorption ameliorated the disease course. Our case supports the notion that in severe cases, immunoadsorption should be considered as first-line therapy instead of IVIG for rapid removal of IgG and thus to hasten recovery and improve functional outcome.
后可逆性脑病综合征(PRES)与无动脉高血压的自身免疫介导的炎性神经病(如吉兰 - 巴雷综合征(GBS))之间的关联是一种罕见且了解甚少的现象。迄今为止,PRES已被描述为轴索性和脱髓鞘性GBS以及米勒 - 费希尔综合征(MFS)病例中静脉注射免疫球蛋白(IVIG)免疫调节治疗后的初始表现、偶然发现或不良事件。我们在此报告一例MFS/比克斯特法夫脑干脑炎(BBE)重叠综合征和非高血压性PRES,其与IVIG治疗在时间上密切相关并导致中风。免疫吸附改善了病程。我们的病例支持这样一种观点,即在严重病例中,应考虑将免疫吸附作为一线治疗而非IVIG,以便快速清除IgG,从而加速恢复并改善功能结局。